On October 16, the gorgeous familyShanghai Haihe Pharmaceutical Research and Development Co. , Ltd. (hereinafter referred to as "Haihe Pharmaceutical"), a joint venture of Huali Family Co., Ltd. (hereinafter referred to as "Huali Family"), and Taiho Pharmaceutical Co., Ltd. (hereinafter referred to as "Taiping Pharmaceutical") have reached an exclusive licensing agreement in Japan for the independently developed PI3Kα inhibitor resolise (CYH33).

This collaboration marks another in-depth collaboration between Haihe Pharmaceuticals and Dapeng Pharmaceuticals, following the development of Glumetinib. It focuses on the development, production, and commercialization of risolide in Japan. Under the agreement, Dapeng Pharmaceuticals will obtain exclusive rights to risolide in Japan, while Haihe Pharmaceuticals will receive an upfront payment, development and sales milestone payments, and royalties based on the drug's sales in Japan.

The cooperation on Resolisab is not accidental, but a renewed collaboration between Haihe Pharmaceuticals and Dapeng Pharmaceuticals based on trust. As early as last year, the two parties reached an exclusive licensing agreement for the MET inhibitor Gumetinib, promoting the launch of this original Chinese anti-cancer drug in Japan. Gumetinib has now been approved for marketing in both China and Japan, becoming a benchmark innovative drug developed by a Chinese domestic pharmaceutical company and successfully launched in the Japanese market.。

The successive implementation of these two collaborations not only demonstrates Dapeng Pharmaceutical's recognition of Haihe Pharmaceutical's R&D capabilities, but also effectively demonstrates the effectiveness of Haihe Pharmaceutical's "China-originated, global expansion" strategy. All of this is inseparable from the strategic support of the Huali Family . Through its equity participation in Haihe Pharmaceutical, the Huali Family provides capital support for its R&D investment and global expansion, enabling the innovative drug 's "road to globalization" to proceed more steadily and rapidly.

https://finance.eastmoney.com/a/202510163536260076.html